Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA director Troy Cox has filed an initial ownership report showing a substantial equity position in the company. He directly holds 309,019 ordinary shares, which include 33,784 ordinary shares to be delivered under a restricted share unit award that vests in full at the issuer’s next annual shareholder meeting, subject to his continued service.
He also holds several share option awards over ordinary shares. These include options over 11,500 shares at an exercise price of 4.0100 per share expiring on June 19, 2029, 162,740 shares at 4.1200 per share expiring on January 1, 2030, and 49,751 shares at 3.0400 per share expiring on June 18, 2035. The filing states that the share options are fully vested and exercisable.
SOPH reports multiple Rule 10b5-1 sales by Jurgi Camblong. The filing lists numerous planned sales of Common stock executed under a 10b5-1 plan between 12/19/2025 and 03/13/2026, including 95,488 shares on 01/09/2026 (amount 491,626.46) and 37,299 shares on 01/22/2026 (amount 209,917.83).
SOPHiA GENETICS files a resale prospectus to register 75,000 ordinary shares issuable upon exercise of a warrant previously issued to Perceptive Credit Holdings IV, LP. The Second Amendment warrant carries an exercise price of $5.1829 per share and is exercisable for cash until 5:00 p.m. Eastern on January 23, 2036.
The company will not receive proceeds from secondary sales by the selling shareholder; however, if the Second Amendment warrants are exercised in full the company could receive up to $388,717.50, which it says would be used for working capital and general corporate purposes. Shares outstanding were 89,321,220 ordinary shares as of December 31, 2025.
SOPHiA GENETICS files an F-3 to register up to 75,000 ordinary shares for resale by a selling shareholder. These shares are issuable upon exercise of a warrant (the "Second Amendment warrant shares") with an exercise price of $5.1829 per share and an exercise period ending at 5:00 p.m., Eastern time, on January 23, 2036.
We will not receive proceeds from resale by the selling shareholder; however, we may receive up to $388,717.50 if the holder exercises all Second Amendment warrant shares, and any such proceeds will be used for working capital and general corporate purposes. As context, share capital registered was 89,321,220 ordinary shares as of December 31, 2025.
SOPHiA GENETICS has filed its annual Form 20-F for the year ended December 31, 2025, presenting IFRS-based consolidated financial statements and extensive risk disclosures. The company had 68,486,338 ordinary shares outstanding as of year-end.
The report describes the SOPHiA DDM Platform, a cloud-based multimodal data analytics solution used across oncology, rare and infectious diseases, cardiology, neurology and other areas. Management highlights numerous forward-looking statements and cautions that actual results may differ materially due to detailed risk factors.
Key risks include challenges expanding platform features and data modalities, dependence on sales and marketing execution and strategic relationships, uncertain reimbursement and market adoption, intense competition, ongoing net losses with no assurance of future profitability, heavy reliance on third parties and key personnel, cybersecurity and data privacy threats, and significant regulatory and IVD approval requirements in the U.S. and Europe.
SOPHiA GENETICS reported strong 2025 revenue growth but remains loss-making. Fourth-quarter revenue reached $21.7 million, up 22% year over year, while full-year revenue rose 19% to $77.3 million. Reported gross margin was 67.4% for 2025, with adjusted gross margin at 74.2%.
The company recorded a 2025 IFRS net loss of $79.0 million and an adjusted EBITDA loss of $41.5 million, both larger than in 2024, though year-over-year adjusted EBITDA deterioration was limited to 3%. Management processed more than 391,000 analyses in 2025 and grew core genomics customers to 528.
For 2026, SOPHiA GENETICS guides to revenue between $92 million and $94 million, implying roughly 20–22% growth, and expects an adjusted EBITDA loss between $29 million and $32 million. The company raised $15.5 million via its at-the-market equity program and expanded its credit facility by $25 million, and targets approaching adjusted EBITDA breakeven by the end of 2026 with a move to positive adjusted EBITDA in the second half of 2027.
Zhenyu Xu submitted a Rule 144 notice reporting proposed sales of Common stock. The filing lists recent 10b5-1 sales by Zhenyu Xu, including sales of 4,000 shares on 02/13/2026 and 4,000 shares on 01/13/2026. The broker shown is Morgan Stanley Smith Barney LLC. The "Securities To Be Sold" section lists 608 Restricted Stock Units (dated 02/18/2026) and 4,000 Founders Shares (dated 06/20/2012).
SOPH submitted a Rule 144 notice for the proposed sale of 684 restricted stock units by the issuer, dated 02/18/2026. The filing also lists prior 10b5-1 sales by Daan Guido Maria Van Well on 12/19/2025, 01/05/2026, 01/06/2026, and 01/20/2026, each showing quantities of 2051, 2056, or 684 shares in the excerpt.